Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been investigated in numerous studies. The aim of this systematic literature review is to collate evidence on the real-world clinical effectiveness of liraglutide. METHODS: A review of publications from Medline, EMBASE, the Cochrane Library, and conference proceedings was conducted to identify observational studies that assessed the clinical effectiveness of liraglutide in real-world clinical practice. This review was conducted according to the National Institute of Health and Care Excellence (NICE) guidance. No language or time limits were applied, except to the conference proceedings (2013-2015). Endpoints for data extraction were decided a priori. Study quality appraisal was done for full-text journal articles. RESULTS: Of 124 publications included in the review, 43 were full-text articles. Liraglutide significantly reduces glycated hemoglobin (HbA1c) within 6 months of initiating treatment (mean change in HbA1c from baseline: -0.9% to -2.2%; HbA1c <7.0%: 29.5-65.0%). The NICE composite endpoint (HbA1c reduction ≥1% and weight reduction ≥3%) was met in 16.9-47.0% of patients with liraglutide treatment. Liraglutide therapy led to a mean change in absolute weight from baseline of -1.3 to -8.65 kg. Liraglutide treatment was well tolerated in patients with T2DM. The rate of occurrence of hypoglycemia with liraglutide monotherapy was ≤0.8%. Hypoglycemia was more common in patients taking antidiabetic medications (0.0-15.2%) together with liraglutide. The beneficial glycemic and weight effect of liraglutide therapy in patients with T2DM was maintained for at least 12 months. CONCLUSION: Evidence from observational studies reflecting real-world clinical practice demonstrates that liraglutide therapy improves glycemic control with a low risk of hypoglycemia, and is associated with significant weight loss in patients with T2DM. These observations are consistent with clinical trial findings. FUNDING: Novo Nordisk A/S, Søborg, Denmark.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“If a patient’s blood glucose level is not decreased to, and maintained at, the individualized target glycated hemoglobin (HbA1c) levels [7], it is recommended that medical treatment with anti-diabetic drugs be initiated.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“GLP-1 RAs mimic the effects of endogenous GLP-1, which regulates plasma glucose levels by stimulating the secretion and biosynthesis of insulin and by inhibiting the secretion of glucagon and by delaying the gastric emptying of food and reducing food intake [8, 9].”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 56
- Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–35. · DOI · Paper page
- Doyle ME, Egan JM. Mechanisms of Action of GLP-1 in the Pancreas. Pharmacol Ther. 2007;113(3):546–93. · DOI · Paper page
- Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78. · DOI · Paper page
- Buse JB, Nauck M, Forst T, Sheu WHH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–24. · DOI · Paper page
- Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56. · DOI · Paper page
- Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407. · DOI · Paper page
- Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–93. · DOI · Paper page
- Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, et al. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016;7(1):76–84. · DOI
- Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, et al. Combination therapy with liraglutide and insulin in Japanese subjects with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016. (Epub ahead of print). · DOI · Paper page
- Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. Centre for Reviews and Dissemination: University of York; 2009.
- Buysschaert M, D’Hooge D, Preumont V, Roots Study Group. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza) in type 2 diabetic patients. Diabetes Metab Syndr. 2015;9(3):139–42. · DOI
- Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffo E, Lupoli R, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. Acta Diabetol. 2015;52(2):331–6. · DOI
- Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4(1):27–40. · DOI
- Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2: résultats d’une enquête nationale rétrospective au Royaume-Uni. Méd Mal Métab. 2014;8(2):177–83.
- Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943–9. · DOI
- Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab. 2014;16(3):273–5. · DOI · Paper page
- Gautier JF, Martinez L, Penfornis A, Eschwege E, Charpentier G, Huret B, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice–EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32(9):838–53. · DOI · Paper page
- Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM. Effectiveness of liraglutide in type II diabetes mellitus management: experience in emirati patients. Clin Med Insights Endocrinol Diabetes. 2015;8:67–72. · DOI
- Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014;6(1):95. · DOI
- Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther. 2015;37(3):574–84. · DOI
- Perušičová J, Skupina, Pithová a pracovní P. Vliv inkretinového mimetika liraglutidu (Victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus 2. typu v diabetologických ordinacích ČR–studie BIVI. Interní medicína pro praxi. 2013;15(5):170–5.
- Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Miner Endocrinol. 2013;38(1):103–12.
- Rigato M, Avogaro A, Fadini GP. Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. J Endocrinol Invest. 2015;38(12):1357–63. · DOI
- Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, et al. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38(1):81–9. · DOI
- Vitagliano G, Nosso G, Cotugno M, Saldalamacchia G, Lupoli R, Griffo E, et al. One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: a retrospective study. G Ital Diabetol Metabol. 2014;34(2):58–63.
- Zavattaro M, Caputo M, Sama MT, Mele C, Chasseur L, Marzullo P, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620–6. · DOI
- Bashier AM, Hussain AA, Abdelgadir EI, Eltinay AT, Thadani P, Abdalla ME, et al. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. J Diabetes Metab Disord. 2015;14:48. · DOI
- Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther. 2014;31(9):986–99. · DOI · Paper page
- DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther. 2014;31(2):202–16. · DOI
- Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A. Efficacy of liraglutide in a real-life cohort. Diabetes Ther. 2014;5(1):193–206. · DOI
- Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Diabetes Metab Syndr. 2015;9(1):30–3. · DOI
- Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med. 2012;5:317–22. · DOI
- Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig. 2013;4(6):571–5. · DOI
- Kondo Y, Satoh S, Osada UN, Terauchi Y. Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J. 2015;62(11):971–80. · DOI
- Li Q, Chitnis A, Hammer M, Langer J. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther. 2014;5(2):579–90. · DOI
- Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O, Escalada-San Martin J, Angel Rubio Herrera M, Lopez de la Torre Casares M. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther. 2015;6(2):173–85. · DOI
- Rizzo MCM, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;13:49. · DOI · Paper page
- Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med. 2014;31(4):403–11. · DOI
- Toyoda M, Yokoyama H, Abe K, Nakamura S, Suzuki D. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106(3):451–7. · DOI
- Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440–3. · DOI · Paper page
- Diaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract. 2014;104(1):92–6. · DOI
- Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, et al. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC Endocr Disord. 2015;15(1):78. · DOI
- Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:706416. · DOI · Paper page
- Kaur P, Mishra SK, Mithal A, Saxena M, Makkar A, Sharma P. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India. Indian J Endocrinol Metab. 2014;18(1):77–82. · DOI
- Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther. 2011;13(11):1139–44. · DOI
- Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147–51. · DOI
- Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta-cell function. J Diabetes Investig. 2013;4(6):585–94. · DOI
- Jepsen P, Johnsen SP, Gillman MW, Sørensen HT. Interpretation of observational studies. Heart. 2004;90(8):956–60. · DOI · Paper page
- Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–59. · DOI · Paper page
- Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968–76. · DOI · Paper page
- Karasik A, Heymann A, Sternberg P, Leshno M, Todorova L, Goldshtein I, et al. Real life effects of liraglutide supports those shown in RCTs. In: Presented at The ISPOR 16th Annual European Congress, Dublin; 2–6th November 2013. · doi:10.1016/j.jval.2013.08.630
- Fatima J, Pearce S. The use of GLP-1 agonist liraglutide: adhereing to guidelines? Diabetic Medicine. 2014;31(Suppl 1):28–123. Abstract P154. Abstracts of the Diabetes UK Professional Conference, 5–7 March 2014.
- Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888–94. · DOI · Paper page
- Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–3. · DOI · Paper page
- Zinman B, Buse J, Falahati S, Moses A. Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies. Diabetologia. 2009;52(Suppl 1):S291.
- Davies MJ, Kela R, Khunti K. Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011;13(3):207–20. · DOI · Paper page
Cited by
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Anholm, C., Kumarathurai, P., Pedersen, L. R., Samkani, A., Walzem, R. L., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.007 · Cited by 75
Metadata
- Authors
- Ostawal, A., Mocevic, E., Kragh, N., & Xu, W.
- Venue
- Diabetes Therapy
- Published
- 2016-06-27
- Volume
- 7
- Issue
- 3
- Pages
- 411-438
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W2473382031
- Cited by
- 86
- References
- 20
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- Funders
- Novo Nordisk A/S
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. https://app.cochat.ai/papers/10.1007/s13300-016-0180-0
- The paper
- Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016). Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Therapy. https://doi.org/10.1007/s13300-016-0180-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.